FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313435877> ?p ?o ?g. }

• W4313435877 endingPage "4" @default.
• W4313435877 startingPage "4" @default.
• W4313435877 abstract "With the spread of multi-drug-resistant (MDR) bacteria and the lack of effective antibiotics to treat them, developing new therapeutic methods and strategies is essential. In this study, we evaluated the antibacterial and antibiofilm activity of different formulations composed of ibuprofen (IBP), acetylsalicylic acid (ASA), and dexamethasone sodium phosphate (DXP) in combination with ciprofloxacin (CIP), gentamicin (GEN), cefepime (FEP), imipenem (IPM), and meropenem (MEM) on clinical isolates of Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) as well as the transcription levels of biofilm-associated genes in the presence of sub-MICs of IBP, ASA, and DXP. The minimal inhibitory concentrations (MICs), minimal biofilm inhibitory concentrations (MBICs), and minimum biofilm eradication concentrations (MBECs) of CIP, GEN, FEP, IPM, and MEM with/without sub-MICs of IBP (200 µg/mL), ASA (200 µg/mL), and DXP (500 µg/mL) for the clinical isolates were determined by the microbroth dilution method. Quantitative real-time-PCR (qPCR) was used to determine the expression levels of biofilm-related genes, including icaA in S. aureus and algD in P. aeruginosa at sub-MICs of IBP, ASA, and DXP. All S. aureus isolates were methicillin-resistant S. aureus (MRSA), and all P. aeruginosa were resistant to carbapenems. IBP decreased the levels of MIC, MBIC, and MBEC for all antibiotic agents in both clinical isolates, except for FEP among P. aeruginosa isolates. In MRSA isolates, ASA decreased the MICs of GEN, FEP, and IPM and the MBICs of IPM and MEM. In P. aeruginosa, ASA decreased the MICs of FEP, IPM, and MEM, the MBICs of FEP and MEM, and the MBEC of FEP. DXP increased the MICs of CIP, GEN, and FEP, and the MBICs of CIP, GEN, and FEP among both clinical isolates. The MBECs of CIP and FEP for MRSA isolates and the MBECs of CIP, GEN, and MEM among P. aeruginosa isolates increased in the presence of DXP. IBP and ASA at 200 µg/mL significantly decreased the transcription level of algD in P. aeruginosa, and IBP significantly decreased the transcription level of icaA in S. aureus. DXP at 500 µg/mL significantly increased the expression levels of algD and icaA genes in S. aureus and P. aeruginosa isolates, respectively. Our findings showed that the formulations containing ASA and IBP have significant effects on decreasing the MIC, MBIC, and MBEC levels of some antibiotics and can down-regulate the expression of biofilm-related genes such as icaA and algD. Therefore, NSAIDs represent appropriate candidates for the design of new antibacterial and antibiofilm therapeutic formulations." @default.
• W4313435877 created "2023-01-06" @default.
• W4313435877 creator A5010509080 @default.
• W4313435877 creator A5011525308 @default.
• W4313435877 creator A5040551434 @default.
• W4313435877 creator A5087815482 @default.
• W4313435877 date "2022-12-20" @default.
• W4313435877 modified "2023-09-27" @default.
• W4313435877 title "Antimicrobial and Antibiofilm Effects of Combinatorial Treatment Formulations of Anti-Inflammatory Drugs—Common Antibiotics against Pathogenic Bacteria" @default.
• W4313435877 cites W129031804 @default.
• W4313435877 cites W1634682499 @default.
• W4313435877 cites W1843235069 @default.
• W4313435877 cites W1975014863 @default.
• W4313435877 cites W1993234669 @default.
• W4313435877 cites W2001760607 @default.
• W4313435877 cites W2013132279 @default.
• W4313435877 cites W2025957152 @default.
• W4313435877 cites W2032453306 @default.
• W4313435877 cites W2042774380 @default.
• W4313435877 cites W2061585919 @default.
• W4313435877 cites W2070337518 @default.
• W4313435877 cites W2073619436 @default.
• W4313435877 cites W2082245936 @default.
• W4313435877 cites W2090950977 @default.
• W4313435877 cites W2107562182 @default.
• W4313435877 cites W2116646070 @default.
• W4313435877 cites W2121665388 @default.
• W4313435877 cites W2123572535 @default.
• W4313435877 cites W2150749808 @default.
• W4313435877 cites W2153164648 @default.
• W4313435877 cites W2405903593 @default.
• W4313435877 cites W2411260633 @default.
• W4313435877 cites W2560508117 @default.
• W4313435877 cites W2563347164 @default.
• W4313435877 cites W2593861288 @default.
• W4313435877 cites W2603946336 @default.
• W4313435877 cites W2725837350 @default.
• W4313435877 cites W2782418238 @default.
• W4313435877 cites W2794808122 @default.
• W4313435877 cites W2801000977 @default.
• W4313435877 cites W2892679831 @default.
• W4313435877 cites W2899214427 @default.
• W4313435877 cites W2955156611 @default.
• W4313435877 cites W2973098004 @default.
• W4313435877 cites W2980031733 @default.
• W4313435877 cites W3004140701 @default.
• W4313435877 cites W3013673383 @default.
• W4313435877 cites W3033150431 @default.
• W4313435877 cites W3046605135 @default.
• W4313435877 cites W3081147093 @default.
• W4313435877 cites W3084062421 @default.
• W4313435877 cites W3093707848 @default.
• W4313435877 cites W3171230204 @default.
• W4313435877 cites W3185083450 @default.
• W4313435877 cites W4211066906 @default.
• W4313435877 doi "https://doi.org/10.3390/pharmaceutics15010004" @default.
• W4313435877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36678634" @default.
• W4313435877 hasPublicationYear "2022" @default.
• W4313435877 type Work @default.
• W4313435877 citedByCount "0" @default.
• W4313435877 crossrefType "journal-article" @default.
• W4313435877 hasAuthorship W4313435877A5010509080 @default.
• W4313435877 hasAuthorship W4313435877A5011525308 @default.
• W4313435877 hasAuthorship W4313435877A5040551434 @default.
• W4313435877 hasAuthorship W4313435877A5087815482 @default.
• W4313435877 hasBestOaLocation W43134358771 @default.
• W4313435877 hasConcept C176947019 @default.
• W4313435877 hasConcept C185592680 @default.
• W4313435877 hasConcept C2775832221 @default.
• W4313435877 hasConcept C2777050379 @default.
• W4313435877 hasConcept C2777637488 @default.
• W4313435877 hasConcept C2778512257 @default.
• W4313435877 hasConcept C2779375183 @default.
• W4313435877 hasConcept C2779489039 @default.
• W4313435877 hasConcept C2779631663 @default.
• W4313435877 hasConcept C4937899 @default.
• W4313435877 hasConcept C501593827 @default.
• W4313435877 hasConcept C523546767 @default.
• W4313435877 hasConcept C54355233 @default.
• W4313435877 hasConcept C58123911 @default.
• W4313435877 hasConcept C86803240 @default.
• W4313435877 hasConcept C89423630 @default.
• W4313435877 hasConcept C94665300 @default.
• W4313435877 hasConceptScore W4313435877C176947019 @default.
• W4313435877 hasConceptScore W4313435877C185592680 @default.
• W4313435877 hasConceptScore W4313435877C2775832221 @default.
• W4313435877 hasConceptScore W4313435877C2777050379 @default.
• W4313435877 hasConceptScore W4313435877C2777637488 @default.
• W4313435877 hasConceptScore W4313435877C2778512257 @default.
• W4313435877 hasConceptScore W4313435877C2779375183 @default.
• W4313435877 hasConceptScore W4313435877C2779489039 @default.
• W4313435877 hasConceptScore W4313435877C2779631663 @default.
• W4313435877 hasConceptScore W4313435877C4937899 @default.
• W4313435877 hasConceptScore W4313435877C501593827 @default.
• W4313435877 hasConceptScore W4313435877C523546767 @default.
• W4313435877 hasConceptScore W4313435877C54355233 @default.
• W4313435877 hasConceptScore W4313435877C58123911 @default.
• W4313435877 hasConceptScore W4313435877C86803240 @default.

• next